United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · IEX Real-Time Price · USD
317.05
-1.96 (-0.61%)
Jul 2, 2024, 4:00 PM EDT - Market closed
United Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for United Therapeutics stock have an average target of 310.4, with a low estimate of 240 and a high estimate of 400. The average target predicts a decrease of -2.10% from the current stock price of 317.05.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for UTHR stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Buy | 5 | 4 | 5 | 5 | 7 | 7 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $325 → $350 | Buy | Maintains | $325 → $350 | +10.39% | Jun 12, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $280 → $300 | Buy | Maintains | $280 → $300 | -5.38% | May 21, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $218 → $240 | Hold | Maintains | $218 → $240 | -24.30% | May 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $300 | Strong Buy | Reiterates | $300 | -5.38% | May 2, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $375 → $400 | Buy | Maintains | $375 → $400 | +26.16% | May 2, 2024 |
Financial Forecast
Revenue This Year
2.80B
from 2.33B
Increased by 20.09%
Revenue Next Year
3.02B
from 2.80B
Increased by 8.16%
EPS This Year
24.82
from 19.81
Increased by 25.30%
EPS Next Year
27.15
from 24.82
Increased by 9.40%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.1B | 3.6B | 3.7B | 4.5B | 5.2B |
| Avg | 2.8B | 3.0B | 3.2B | 3.5B | 3.6B |
| Low | 2.5B | 2.6B | 2.7B | 3.0B | 2.9B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 32.0% | 28.0% | 23.9% | 41.1% | 48.9% |
| Avg | 20.1% | 8.2% | 5.1% | 9.4% | 3.6% |
| Low | 9.0% | -8.2% | -9.1% | -6.6% | -17.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 30.33 | 39.53 | 31.99 | 34.78 | 36.09 |
| Avg | 24.82 | 27.15 | 26.91 | 27.73 | 27.61 |
| Low | 20.95 | 21.24 | 16.57 | 21.67 | 19.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 53.1% | 59.3% | 17.8% | 29.2% | 30.2% |
| Avg | 25.3% | 9.4% | -0.9% | 3.0% | -0.4% |
| Low | 5.8% | -14.4% | -39.0% | -19.5% | -30.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.